Search Results for: PRKACA

219 interactions involving PRKACA - protein kinase cAMP-activated catalytic subunit alpha found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
GNMT glycine N-methyltransferase
  • Metabolism of ingested SeMet, Sec, MeSec into H2Se
  • Glyoxylate metabolism and glycine degradation
  • Ademetionine
  • Glycine
  • S-adenosyl-L-homocysteine
  • Hypermethioninemia; Methionine adenosyltransferase deficiency; S-adenosylhomocysteine hydrolase deficiency
GP1BB glycoprotein Ib platelet subunit beta
  • Intrinsic Pathway of Fibrin Clot Formation
  • GP1b-IX-V activation signalling
  • Platelet Adhesion to exposed collagen
  • Platelet Aggregation (Plug Formation)
  • Defective F9 activation
  • Bernard-Soulier syndrome; Giant platelet syndrome
GRIA1 glutamate ionotropic receptor AMPA type subunit 1
  • COPII-mediated vesicle transport
  • Activation of AMPA receptors
  • Trafficking of AMPA receptors
  • Trafficking of GluR2-containing AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Cargo concentration in the ER
  • Synaptic adhesion-like molecules
  • Long-term potentiation
  • Glutamic acid
  • Butabarbital
  • Lamotrigine
  • Isoflurane
  • Ethanol
  • Methoxyflurane
  • Desflurane
  • Sevoflurane
  • Talampanel
  • CX-717
  • CX516
  • Perampanel
  • Tianeptine
  • Fluciclovine (18F)
GRIA4 glutamate ionotropic receptor AMPA type subunit 4
  • Activation of AMPA receptors
  • Trafficking of AMPA receptors
  • Trafficking of GluR2-containing AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Synaptic adhesion-like molecules
  • Glutamic acid
  • Butabarbital
  • Ethanol
  • Talampanel
  • CX-717
  • Fluciclovine (18F)
GRK2 G protein-coupled receptor kinase 2
  • Calmodulin induced events
  • G alpha (q) signalling events
  • G alpha (s) signalling events
  • Activation of SMO
  • Activation of SMO
  • Cargo recognition for clathrin-mediated endocytosis
  • ATP
GSK3A glycogen synthase kinase 3 alpha
  • AKT phosphorylates targets in the cytosol
  • XBP1(S) activates chaperone genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Suppression of apoptosis
  • Replication of the SARS-CoV-1 genome
  • Replication of the SARS-CoV-2 genome
  • Fostamatinib
GSK3B glycogen synthase kinase 3 beta
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • AKT phosphorylates targets in the cytosol
  • Regulation of HSF1-mediated heat shock response
  • CRMPs in Sema3A signaling
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • B-WICH complex positively regulates rRNA expression
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ubiquitin-dependent degradation of Cyclin D
  • Regulation of RUNX2 expression and activity
  • Replication of the SARS-CoV-1 genome
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Replication of the SARS-CoV-2 genome
  • Lithium cation
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • SB-409513
  • AR-AO-14418
  • Staurosporine
  • Indirubin-3'-monoxime
  • 6-bromoindirubin-3'-oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • Fostamatinib
  • Tideglusib
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate
GUSB glucuronidase beta
  • HS-GAG degradation
  • Hyaluronan uptake and degradation
  • MPS VII - Sly syndrome
  • Neutrophil degranulation
  • Mucopolysaccharidosis type VII (MPS7); Sly syndrome
GYS1 glycogen synthase 1
  • Glycogen synthesis
  • Myoclonic epilepsy of Lafora
  • Glycogen storage disease type XV (GYG1)
  • Glycogen storage disease type 0 (muscle GYS1)
  • Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
HAND1 heart and neural crest derivatives expressed 1
HAND2 heart and neural crest derivatives expressed 2
  • Transcriptional regulation by RUNX2
HDAC1 histone deacetylase 1
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • p75NTR negatively regulates cell cycle via SC1
  • Formation of the beta-catenin:TCF transactivating complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HDACs deacetylate histones
  • Notch-HLH transcription pathway
  • Deactivation of the beta-catenin transactivating complex
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • NoRC negatively regulates rRNA expression
  • SUMOylation of chromatin organization proteins
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Regulation of TP53 Activity through Acetylation
  • G1/S-Specific Transcription
  • RNA Polymerase I Transcription Initiation
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Estrogen-dependent gene expression
  • Loss of MECP2 binding ability to 5mC-DNA
  • Regulation of MECP2 expression and activity
  • MECP2 regulates neuronal receptors and channels
  • MECP2 regulates transcription of neuronal ligands
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Potential therapeutics for SARS
  • Factors involved in megakaryocyte development and platelet production
  • Arsenic trioxide
  • Zinc
  • Vorinostat
  • Belinostat
  • Pracinostat
  • Romidepsin
  • Panobinostat
  • Fingolimod
  • Mocetinostat
  • Abexinostat
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
HDAC8 histone deacetylase 8
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HDACs deacetylate histones
  • Notch-HLH transcription pathway
  • Iron
  • Zinc
  • Vorinostat
  • 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
  • N-Hydroxy-4-(Methyl{[5-(2-Pyridinyl)-2-Thienyl]Sulfonyl}Amino)Benzamide
  • Trichostatin A
  • Belinostat
  • Panobinostat
  • (2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide
  • 5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE
  • Coumarin 120
  • Zinc acetate
  • Ferrous gluconate
  • Ferrous succinate
  • Ferrous ascorbate
  • Ferrous fumarate
  • Ferrous glycine sulfate
  • Zinc chloride
  • Zinc sulfate, unspecified form
HIF1A hypoxia inducible factor 1 subunit alpha
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Cellular response to hypoxia
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Circadian Clock
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Expression
  • PTK6 promotes HIF1A stabilization
  • Neddylation
  • Carvedilol
  • Hydralazine
  • 2-Methoxyestradiol
  • ENMD-1198
  • PX-478
  • FG-2216
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • NADH
  • Pravastatin
  • Lovastatin
  • Cerivastatin
  • Simvastatin
  • Atorvastatin
  • Fluvastatin
  • Rosuvastatin
  • Coenzyme A
  • (S)-Hmg-Coa
  • Nicotinamide adenine dinucleotide phosphate
  • Meglutol
  • 1,4-Dithiothreitol
  • TAK-475
  • Mevastatin
  • Pitavastatin
  • Cannabidiol
  • Medical Cannabis
  • Nabiximols
HMGN1 high mobility group nucleosome binding domain 1
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
HMGN2 high mobility group nucleosomal binding domain 2
HNF4A hepatocyte nuclear factor 4 alpha
  • Nuclear Receptor transcription pathway
  • Lauric acid
  • AVI-4557
  • Myristic acid
  • Maturity onset diabetes of the young (MODY)
HNRNPD heterogeneous nuclear ribonucleoprotein D
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • Artenimol
HSP90AA1 heat shock protein 90 alpha family class A member 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • RHOBTB2 GTPase cycle
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Potential therapeutics for SARS
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • CCT-018159
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Polaprezinc
  • Alvespimycin

Page 5 out of 11 pages